<DOC>
	<DOCNO>NCT02115815</DOCNO>
	<brief_summary>The purpose study determine administration single ascend intramuscular dos RSV sF antigen MEDI7510 safe well tolerate adult 60 year old healthy stable , chronic underlie medical condition .</brief_summary>
	<brief_title>A Study Evaluate Safety Respiratory Syncytial Virus Vaccine MEDI7510 Older Adults</brief_title>
	<detailed_description>A phase 1a , first time human , double-blind , randomize , placebo-controlled , cohort escalation study evaluate safety tolerability single ascend intramuscular dose RSV sF MEDI7510 placebo . Approximately 146 participant enrol 3 US study center randomize 5:1 ratio cohort describe : Cohort 1 : RSV sF 20 microgram ( mcg ) ( n=20 ) placebo ( n=4 ) Cohort 1a : MEDI7510 ( 20 mcg RSV sF 2.5 mcg glucopyranosyl lipid A ( GLA ) + 2 % weight per volume stable emulsion ( n=20 ) placebo ( n=4 ) Cohort 2 : RSV sF 50 mcg ( n=20 ) placebo ( n=4 ) Cohort 2a : MEDI7510 ( 50 mcg RSV sF 2.5 mcg glucopyranosyl lipid A ( GLA ) + 2 % weight per volume stable emulsion ( n=20 ) placebo ( n=4 ) Cohort 3 : 80 mcg RSV sF ( n=20 ) placebo ( n=4 ) Cohort 3a : MEDI7510 ( 80 mcg RSV sF 2.5 mcg glucopyranosyl lipid A ( GLA ) + 2 % weight per volume stable emulsion ( n=20 ) placebo ( n=4 )</detailed_description>
	<criteria>Age great equal 60 year Written inform consent locally require authorization obtain prior protocol related procedure Ambulatory ambulatory assistance ( institutionalize , bedridden , homebound Weight 110 Pounds ( lb ) Hemoglobin within normal range age gender History allergy component vaccine Pregnancy potential become pregnant study . Females menstrual period within 12 month prior study enrollment undergoing fertility treatment plan undergo fertility treatment study period exclude Any unstable chronic medical condition , include one result change therapy ( medication ) 30 day prior randomization hospitalization previous year might predict result hospitalization year enrollment . Participant severe , untreated uncontrolled underlying medical disease might either compromise participant safety affect ability ass safety investigational product exclude Clinically significant abnormality Screening laboratory assessment Screening electrocardiogram ( ECG ) History hepatitis B hepatitis C infection Cognitive disorder inform consent obtain directly participant Previous vaccination respiratory syncytial virus ( RSV ) History allergy egg adulthood History current autoimmune disorder Immunosuppression cause disease , include human immunodeficiency virus ( HIV ) , medication . Any oral prednisone dose within 30 day enrollment plan dose within 360day followup period would disqualify . History splenectomy condition affect splenic function History cancer within precede 5 year treat nonmelanoma skin cancer Body Mass Index 40 high Significant infection acute illness , include fever 100 fahrenheit ( F ) day prior day randomization Receipt nonstudy vaccine within 30 day prior study dose expect receipt nonstudy vaccine within 30 day study dose Receipt investigational product 90 day prior randomization expect receipt investigational product period study followup Receipt immunoglobulin blood product within 4 month study dose ( 120 day ) expect receipt investigational product period study followup History thrombocytopenia bleed disorder use anticoagulant . Participants receive drug antiplatelet activity nonsteroidal antiinflammatory drug , clopidogrel aspirin exclude Expected receipt antipyretic analgesic medication daily every day basis randomization 72 hour receipt investigational product ( IP ) [ daily dose 163 milligram ( mg ) high consider contraindication enrollment ] Participants significant scarring , tattoo , abrasion , cut , infection deltoid region arm , principle investigator 's ( PI ) opinion , could interfere evaluation injection site local reaction Concurrent enrollment another clinical study involve invasive clinical procedure , include phlebotomy History alcohol drug abuse psychiatric disorder PI 's opinion would affect participant safety compliance study Employees individual directly involve conduct study , individual involve conduct study , immediate family member individual .</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Respiratory Syncytial Virus ( RSV )</keyword>
	<keyword>MEDI7510</keyword>
</DOC>